REGENERATIVE MEDICINE CLINIC BUSINESS PLAN

I. Executive Summary

Company Description

Company name: To be announced. We are a modern U.S.-based medical practice launching in 2026 that operates in the regenerative medicine sector and delivers non-surgical, minimally invasive care for chronic pain and injuries. Our core services include diagnostic ultrasound-guided interventions and on-site biologics preparation in a dedicated lab, delivered by a team of board-certified practitioners. One-liner: Restorative, non-surgical care using advanced diagnostics and on-site biologics.

We operate on a fee-for-service model prioritizing patient outcomes and clinical excellence. Primary activities are patient assessment, ultrasound diagnostics, biologics preparation, image-guided procedures, and personalized follow-up plans. We target adults with chronic musculoskeletal pain and sports injuries who seek alternatives to surgery. Short-term goals: open clinic and reach break-even within 12 months. Long-term goals: scale to two additional sites and publish clinical outcomes within five years. One-liner: Scalable clinic focused on measurable outcomes and clinical expansion.

Problem

Millions of Americans live with chronic joint pain and degenerative musculoskeletal conditions that standard care treats primarily with long-term medication or invasive surgery, causing prolonged downtime, painful recoveries, and incomplete restoration of function. These care pathways produce repeated procedures, ongoing medication costs, lost workdays, and reduced ability to work or exercise.

The Austin-area market lacks widely available, non-surgical options that deliver durable tissue repair, not just symptom control. Our 2026 clinic—fee-for-service, staffed by board-certified practitioners, using diagnostic ultrasound and an on-site biologics lab—fills this gap by offering advanced, minimally invasive regenerative treatments tailored to restore function. One clear fact: patients need effective tissue repair options that standard care does not reliably provide.

Solution

Millions of Americans live with chronic pain and degenerative joint conditions that are often managed with long-term medication or invasive surgery. Our clinic launches in 2026 to offer advanced, minimally invasive regenerative therapies — Platelet-Rich Plasma (PRP) and cellular therapies — delivered with ultrasound-guided injections as a safe, non-surgical alternative that targets tissue repair, reduces inflammation, and restores mobility.

Precision injections that stimulate tissue repair and avoid major surgery. Core outcomes: pain relief, shorter recovery, preserved function; primary indications: tendinopathies, osteoarthritis, and sports injuries.

Mission Statement

Restore mobility and eliminate chronic pain by delivering sophisticated, non‑surgical regenerative treatments that use the body’s natural healing mechanisms. We commit to clinical excellence, patient‑centric care, and the highest standards of medical integrity while empowering people to reclaim active lives and better quality of life. Our goal is to be the premier destination for regenerative therapies in the United States through measurable outcomes and ethical practice.

Key Success Factors

These factors drive clinical quality, patient flow, margins, and rapid breakeven.

• Experienced medical leadership: Medical Director and Senior Regenerative Physicians ensure clinical credibility and outcomes.
• Advanced clinical facility: State-of-the-art clinic and diagnostic equipment enable precise, effective treatments.
• Reliable patient acquisition: Robust physician referral network plus targeted digital marketing sustain a steady intake.
• High-margin revenue model: Direct fee-for-service pricing with tight COGS and variable cost control preserves profitability.
• Fast breakeven: Achieves financial stability within two months, enabling swift scaling.

Financial Summary

The clinic projects rapid scale and strong profitability over five years.

Financial requirements: minimum cash position $803,000 (Feb-26) and planned capital expenditures total $345,500; returns: IRR 23% and ROE 46.51%, breakeven Feb-26, payback 10 months.

Overall outlook: high-growth, capital-efficient model with strong investor returns.

Funding Requirements

Minimum cash required is $803,000 by Feb-26 to fund capex, initial staffing, two months of fixed costs, and a working-capital buffer.

Projected revenue grows from $1,779,000 in Year 1 to $26,539,000 by Year 5; EBITDA rises from $626,000 (2026) to $20,015,000 (2030); breakeven is Feb‑2026, payback 10 months, IRR 23%, ROE 46.51%.